Article
Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.
International journal of oncology - 1 Sept 2006
Becker J C, Müller-Tidow C, Stolte M, Fujimori T, Tidow N, Ilea A M, Brandts C, Tickenbrock L, Serve H, Berdel W E, Domschke W, Pohle T
Abstract excerpt
The epidermal growth factor receptor (EGFR) is highly expressed in gastric cancer indicating its suitability as a target for receptor tyrosine kinase (RTK) inhibitors. In the current study we explored the role of EGFR and its potential use as a therapeutic target in gastric cancer. First we analyzed 66 gastric cancer samples of Asian and Caucasian patients for the presence of EGFR mutations. No activating EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.